Antiarrhythmic Pharmacology: Vaughan-Williams Classification Made Clinical - podcast episode cover

Antiarrhythmic Pharmacology: Vaughan-Williams Classification Made Clinical

Feb 19, 202632 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

In this episode, we take a focused deep dive into antiarrhythmic medications, breaking down the Vaughan-Williams classification system and translating it into practical nursing knowledge. We’ll review how Class I (sodium channel blockers), Class II (beta-blockers), Class III (potassium channel blockers), and Class IV (calcium channel blockers) alter cardiac conduction, refractoriness, and automaticity to restore rhythm stability. Key prototypes such as amiodarone, lidocaine, metoprolol, and diltiazem are discussed with attention to their mechanisms of action, clinical indications, and major adverse effects. We’ll also highlight critical safety concerns, including QT prolongation, proarrhythmias, organ toxicity, and drug interactions. Throughout the episode, we emphasize essential nursing responsibilities—continuous ECG monitoring, hemodynamic assessment, electrolyte management, and patient education—to ensure safe and effective rhythm control. This episode equips nurses with the pharmacologic framework needed to manage complex dysrhythmias with confidence and clinical precision.

For the best experience, listen in Metacast app for iOS or Android